secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-03-13T23:59:59+00:00
Accession:  0001493152-26-009986
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity 2025 revenue $6.2M; CyPath Lung revenue up 87% YoY, net loss $14.9M
-------------------------------------------------------------------------------

- Total revenue $6.2M, down 34% from $9.4M in 2024 due to discontinuing unprofitable pathology services.
- CyPath Lung revenue increased 87% YoY; tests performed up 99%, physician orders up 67%.
- Net loss $14.9M vs $9.0M in 2024, driven by warrant fair value changes and higher commercialization costs.
- Cash $6.5M at year-end; raised $16.9M in equity in 2025. Guidance: >100% CyPath Lung unit sales growth in 2026.
- Appointed Gordon Downie MD PhD as CMO; Roberto Rios CPA and John Oppenheimer MD to board of directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226009986/0001493152-26-009986-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226009986/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-009986

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer